CYCC
Cyclacel Pharmaceuticals Inc
NASDAQ: CYCC · HEALTHCARE · BIOTECHNOLOGY
$6.37
+0.00% today
Updated 2026-04-29
Market cap
$14.25M
P/E ratio
0.00
P/S ratio
1,425.11x
EPS (TTM)
$7,123.50
Dividend yield
—
52W range
$3 – $98
Volume
—
Cyclacel Pharmaceuticals Inc (CYCC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-103,580.00%
ROE
-276.80%
ROA
-102.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2005 | $356000.00 | $-18.05M | -271.35% | -5,835.67% | -5,069.66% |
| 2006 | $387000.00 | $-29.26M | -5,379.33% | -8,620.67% | -7,560.21% |
| 2007 | $129000.00 | $-24.05M | -15,069.77% | -25,222.48% | -18,645.74% |
| 2008 | $877000.00 | $-40.39M | 51.08% | -3,851.20% | -4,605.02% |
| 2009 | $911000.00 | $-19.57M | 40.18% | -1,969.05% | -2,148.19% |
| 2010 | $686000.00 | $-16.02M | 39.07% | -2,371.14% | -2,335.42% |
| 2011 | $699000.00 | $-15.24M | 48.50% | -2,344.49% | -2,180.69% |
| 2012 | $69000.00 | $-13.19M | -9,453.62% | -21,888.41% | -19,110.14% |
| 2013 | $1.08M | $-10.15M | -940.31% | -1,658.12% | -936.62% |
| 2014 | $1.73M | $-19.39M | -954.04% | -1,293.94% | -1,118.05% |
| 2015 | $1.94M | $-14.34M | -536.93% | -831.79% | -737.76% |
| 2016 | $843000.00 | $-11.79M | -1,024.20% | -1,678.53% | -1,398.70% |
| 2017 | $0.00 | $-7.47M | — | — | — |
| 2018 | $150000.00 | $-7.29M | -2,784.67% | -6,365.33% | -4,858.67% |
| 2019 | $0.00 | $-7.83M | — | — | — |
| 2020 | $5877.00 | $-8.45M | -340.31% | -180,976.69% | -143,695.76% |
| 2021 | $0.00 | $-18.89M | — | — | — |
| 2022 | $373000.00 | $-21.20M | -8.58% | -7,414.48% | -5,683.11% |
| 2023 | $420000.00 | $-22.55M | 100.00% | -6,060.24% | -5,370.24% |
| 2024 | $43000.00 | $-11.21M | 100.00% | -27,916.28% | -26,074.42% |